Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475531 | 0.84 | KMT2A (0.76) | KMT2AKDM4ERAB9ANPSR1 | |
| SCHEMBL3476913 | 0.81 | KMT2A (0.71) | KMT2A | |
| SCHEMBL99369 | 0.79 | KMT2A (0.78) | KMT2A | |
| SCHEMBL99129 | 0.79 | KMT2A (0.62) | KMT2AKDM4ERAB9ANPSR1 | |
| SCHEMBL3477493 | 0.79 | KMT2A (0.74) | KMT2A | |
| SCHEMBL135329 | 0.78 | KMT2A (0.64) | KMT2AMEN1KDM4ERAB9ANPSR1 | |
| SCHEMBL99096 | 0.78 | KMT2A (0.82) | KMT2A | |
| SCHEMBL142032 | 0.77 | KMT2A (0.78) | KMT2AMEN1 | |
| SCHEMBL135608 | 0.77 | KMT2A (0.63) | KMT2A | |
| SCHEMBL133423 | 0.77 | KMT2A (0.71) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465604-B2 | Functional cure of retroviral infection | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-11-11 | — | — | US | claimed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | claimed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | claimed |
| US-12465604-B2 | Functional cure of retroviral infection | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-11-11 | — | — | US | disclosed |
| EP-2430029-B1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | UNIV LEUVEN KATH (BE) | 2018-01-10 | — | — | EP | disclosed |
| US-9499563-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2016-11-22 | — | — | US | disclosed |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | CISTIM LEUVEN VZW (BE) | 2014-10-02 | — | — | US | disclosed |
| US-8785638-B2 | Thieno [2, 3-B] pyridine derivatives as viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465604-B2 | Functional cure of retroviral infection | HDLBP, VSIG8, TNFSF11 | KMT2A 2356/4885MEN1 4293/4885KDM4E 2139/4885 |
| US-20140296272-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | KMT2A 2903/4885MEN1 4548/4885KDM4E 827/4885 |
| US-20120059028-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | TYMP, DUT, MAVS | KMT2A 2903/4885MEN1 4548/4885KDM4E 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.